LL-191 is under clinical development by Nalo Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LL-191’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LL-191 is under development for the treatment of non-small cell lung cancer (NSCLC) with EGFR Exon-20 insertion mutation. The drug candidate is administered through oral route.
For a complete picture of LL-191’s drug-specific PTSR and LoA scores, buy the report here.